This has been a lively year for HIV research says an i-base report. Even though only one new drug was approved (a once-daily version of raltegravir) several key generic...Pharmacology
For a rich country that is a global hub for pharma companies, Switzerland is going to extraordinary lengths to avoid hepatitis C patients having to pay for pricey...HIV/AIDS
Patients with HIV experienced a significantly higher rate of virologic suppression after taking Gilead’s Genvoya (elivitegravir-cobicistat-emtricitabine-tenofovir...Infectious Diseases
France will provide access to hepatitis C treatment with direct-acting antivirals to everyone diagnosed with hepatitis C from September 2016, and will begin to provide...
